Cerebrolysin is the odd one out on this list: it is not a single peptide at all. It is a mixture of small peptides and free amino acids, manufactured from purified pig (porcine) brain tissue1. It is sold as a "neurotrophic" agent — meaning it is claimed to nourish and protect nerve cells — and it is used widely for stroke and dementia in Russia, China, and Eastern Europe. But when independent reviewers pool the trials, the benefit largely evaporates. Understanding what Cerebrolysin *is* — an animal-derived biological soup, not a defined drug — is the key to reading its evidence.
In plain terms: it is a pig-brain-derived peptide mixture, marketed for the brain, with a much weaker evidence base than its popularity suggests.
What it is
Most peptides in this library are single, defined molecules with a known sequence. Cerebrolysin is different. It is produced by breaking down purified porcine (pig) brain proteins into a mixture of low-molecular-weight peptides and free amino acids1. There is no single "active ingredient" you can name; the product is the whole blend.
That origin creates two immediate problems for anyone judging it:
- Undefined composition — because it is a mixture from animal tissue, exactly which components do what is hard to establish.
- Batch consistency — a biological extract is harder to make identical batch-to-batch than a synthesised single peptide.
In plain terms: it is closer to a standardised brain extract than to a clean, single-molecule drug.
How it is claimed to work
Cerebrolysin is marketed as neurotrophic and neuroprotective. "Neurotrophic" means nerve-nourishing — the idea is that its peptide fragments mimic the body's own growth factors that keep neurons healthy and help them survive injury2. Proponents propose it supports neuron survival after events like stroke and slows nerve-cell loss in dementia.
That is the theory. It is biologically plausible — but plausibility is not proof, and this is exactly where the honest reading diverges from the marketing.
In plain terms: the pitch is "it feeds and shields brain cells." The trials are what decide whether that pitch holds.
What the studies actually found
Cerebrolysin has been tested in real human trials — so it sits at the "clinical" evidence level — but the independent verdicts are underwhelming. Cochrane reviews (widely regarded as among the most rigorous, least conflicted evidence syntheses) are the key sources here. Note the model:
| Study | Model / level | Key result | Year |
|---|---|---|---|
| Cui et al. — Cochrane2 | Human (6 RCTs, ~597 patients, vascular dementia) | Some cognition/function signals, but limited by heterogeneity and high risk of bias; benefits, if any, may be too small to matter | 2019 |
| Ziganshina et al. — Cochrane1 | Human (RCTs, acute ischaemic stroke) | No convincing benefit on death or dependency; a signal of increased non-fatal serious adverse events | 2023 |
The pattern: in the two conditions it is most used for, the best independent evidence is weak, inconsistent, and bias-prone — and in stroke there was even a safety signal (more non-fatal serious adverse events with Cerebrolysin)1.
The evidence at a glance
| Property | Cerebrolysin |
|---|---|
| Type | Mixture of peptides + free amino acids (not a single peptide) |
| Source | Purified porcine (pig) brain tissue |
| Marketed as | Neurotrophic / neuroprotective |
| Main uses | Acute ischaemic stroke; vascular dementia |
| Independent verdict (stroke) | No convincing benefit; possible increase in serious adverse events1 |
| Independent verdict (dementia) | Weak, high-risk-of-bias evidence; effect may be too small to matter2 |
| US status | Not FDA-approved |
The honest limits
Two things are worth stating plainly. First, wide use is not the same as strong evidence. Cerebrolysin is popular in several countries, but popularity reflects registration history and prescribing habits, not necessarily proven benefit — the independent reviews are clear that the supporting data is weak21. Second, the animal-mixture origin is a genuine limitation: an undefined porcine-brain extract is harder to standardise and study than a single synthetic peptide, which is part of why its trials are so hard to interpret.
It is also not FDA-approved and not an approved medicine in the US. This page explains what Cerebrolysin is and what the trials showed — not how to use it — and takes no position on sourcing.
Latest research
- The 2023 Cochrane stroke review is the most important recent word: no convincing benefit for acute ischaemic stroke, plus a signal of increased non-fatal serious adverse events1. That is a meaningfully cautious update.
- The 2019 Cochrane vascular-dementia review likewise concluded the evidence is too weak and bias-prone to confirm a clinically meaningful benefit2.
- The core problem is unchanged: as an undefined porcine-brain peptide mixture, Cerebrolysin remains hard to standardise and to study rigorously — the reason its evidence base has stayed thin despite decades of use.
The short version
Cerebrolysin is not a single peptide but a porcine (pig) brain-derived mixture of peptides and amino acids, marketed as neurotrophic and used widely for stroke and dementia. Independent Cochrane reviews find no convincing benefit in acute ischaemic stroke (with a signal of more serious adverse events) and only weak, bias-prone evidence in vascular dementia12. It is not FDA-approved. Educational overview only, not medical advice. For context, see what are research peptides.